Efficacy of Regorafenib and Trifluridine/Tipiracil According to Extended RAS Evaluation in Advanced Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Analysis

ConclusionsOur data demonstrate thatRAS mutations do not affect outcome in rego-treated patients as well as TFD/TPI-treated patients. Nevertheless, a trend toward a higher efficacy of rego inRAS-mutated (in particular codon 12, rareRAS mutations, and G12D) patients has been recorded. The rego-TFD/TPI sequence seems to be superior to the reverse sequence in patients carrying anRAS codon 12 mutation, although the impact of other factors as disease burden or performance status cannot be excluded.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research